An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Content (measure theory)

10.1017/s0317167100026391

Cite

Citations (4)

Deep brain stimulation for dystonia

Movement Disorders (2011)

Anthony E. Lang

Movement Disorders

10.1002/mds.23554

Cite

Citations (4)

Issue Information

Movement Disorders Clinical Practice (2016)

Kailash P. Bhatia Marcelo Merello Cathy Krendel Brenda Stout Günther Deuschl

Movement Disorders Clinical Practice-is an online-only journal committed to publishing high quality peer reviewed articles related to clinical aspects of movement disorders which broadly include phenomenology (interesting case/case series/rarities), investigative (for e.g.genetics, imaging), translational (phenotype-genotype or other) and treatment aspects (clinical guidelines, diagnostic and treatment algorithms).In addition the journal will encourage the publication of educative material (solicited and unsolicited reviews), clinical-pathological cases, drug trials results and task force reports related to the fi eld of movement disorders.MDCP encourages the submission of multimedia material accompanying all types of articles.

10.1002/mdc3.12327

Cite

Citations (0)

Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease

Movement Disorders (2010)

Steven R. Schwid Janice Bausch David Oakes Lynn M. Schuchter Caroline M. Tanner

We performed a placebo-controlled trial of CEP-1347, an inhibitor of neuronal apoptotic cell death, in patients with early Parkinson's disease (PD) to determine whether long-term therapy would slow disability progression. This also provided an opportunity to monitor cancer incidence in a large cohort of PD patients followed prospectively including periods before and after patients developed disability requiring dopaminergic therapy. This was a multicenter study of 806 patients with early PD, without disability requiring dopaminergic therapy, assigned randomly to placebo or one of three doses of CEP-1347. Patients were monitored for an average of 1.8 years (1,467 patient-years) with routine cancer screening evaluations and annual skin examinations by a dermatologist. There was no significant excess of cancers among patients taking CEP-1347 compared with placebo for any cancer type (all P > 0.1). Nonmelanoma skin cancers were the most common cancer type observed. The incidence of melanomas was 20.9 times that predicted in the general population. Most melanomas occurred in patients who had never taken dopaminergic therapy. We found no evidence that CEP-1347 affected cancer incidence within 2 years of follow-up. Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted.

10.1002/mds.23006

Cite

Citations (27)

Movement Disorders (2008)

Susan H. Fox Anthony E. Lang

Long term levodopa therapy in Parkinson's disease (PD) results in a range of problems. These include fluctuations in FD symptoms termed motor fluctuations, as well as non-motor symptoms, termed non-motor fluctuations. Here we review the phenomenology and methods of assessing these levodopa-related complications. © 2008 Movement Disorder Society

Movement Disorders

Motor symptoms

10.1002/mds.22021

Cite

Citations (107)

Efficacy and Safety of BIIB092 in Patients with Progressive Supranuclear Palsy: PASSPORT Phase 2 Study Design (P6.073)

Neurology (2018)

Tien Dam Adam L. Boxer Lawrence I. Golbe Günter U. Höglinger Huw R. Morris

To describe the design of the PASSPORT study (NCT03068468) in progressive supranuclear palsy (PSP), a neurodegenerative disease characterized by atypical Parkinsonism and tau pathology.

10.1212/wnl.90.15_supplement.p6.073

Cite

Citations (6)

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches

The Lancet Neurology (2017)

Adam L. Boxer Jin‐Tai Yu Lawrence I. Golbe Irene Litvan Anthony E. Lang

Neuropathology

Chronic traumatic encephalopathy

Corticobasal degeneration

Movement Disorders

10.1016/s1474-4422(17)30157-6

Cite

Citations (393)

Globus pallidus internus pallidotomy for generalized dystonia

Movement Disorders (1997)

Andrés M. Lozano Rajeev Kumar Robert E. Gross Nir Giladi William D. Hutchison

Abstract The authors present a young boy with severe generalized dystonia treated with bilateral simultaneous pallidotomy. Microelectrode recordings with the patient under propofol anesthesia showed that the mean discharge rate of globus pallidus internus (GPi) neurons was between 21 and 31 Hz. This contracts sharply with the mean GPi neuronal firing rates of approximately 80 Hz that are characteristic of Parkinson's disease. The patient had no immediate benefit from surgery, but a progressive improvement in both axial and limb dystonia began within 3 days. The Burke‐Fahn‐Marsden scores were 75 (maximum possible = 120) at baseline, 52 at 5 days, and 16 at 3 months after surgery. The mechanism of action of pallidotoy for dystonia and the reasons for the delayed and progressive improvement are unknown. Nevertheless, the magnitude of the improvement and the safety of the procedure in this one patient warrant a careful evaluation of pallidotomy for dystonia.

Pallidotomy

10.1002/mds.870120606

Cite

Citations (325)

The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway

Human Molecular Genetics (2004)

Hsien-Yang Lee Ying Xu Yong Huang Andrew H. Ahn Georg Auburger

Paroxysmal non-kinesigenic dyskinesia (PNKD) is characterized by spontaneous hyperkinetic attacks that are precipitated by alcohol, coffee, stress and fatigue. We report mutations in the myofibrillogenesis regulator 1 (MR-1) gene causing PNKD in 50 individuals from eight families. The mutations cause changes (Ala to Val) in the N-terminal region of two MR-1 isoforms. The MR-1L isoform is specifically expressed in brain and is localized to the cell membrane while the MR-1S isoform is ubiquitously expressed and shows diffuse cytoplasmic and nuclear localization. Bioinformatic analysis reveals that the MR-1 gene is homologous to the hydroxyacylglutathione hydrolase (HAGH) gene. HAGH functions in a pathway to detoxify methylglyoxal, a compound present in coffee and alcoholic beverages and produced as a by-product of oxidative stress. Our results suggest a mechanism whereby alcohol, coffee and stress may act as precipitants of attacks in PNKD. Stress response pathways will be important areas for elucidation of episodic disease genetics where stress is a common precipitant of many common disorders like epilepsy, migraine and cardiac arrhythmias.

Paroxysmal dyskinesia

10.1093/hmg/ddh330

Cite

Citations (187)

Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease

Annals of Neurology (2004)

Anthony E. Lang José Á. Obeso

Nigrostriatal pathway

10.1002/ana.20102

Cite

Citations (103)